1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Xaluritamig: new trials by email Literature Review of Xaluritamig trials Research Report on Xaluritamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Amgen | 750 | 2025-11-28 | 2026-10-20 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) Xaluritamig, Abiraterone, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Amgen | 707 | 2024-12-09 | 2026-05-15 |
Prostatic Neoplasms (2) · Neoplasms (1)
Amgen (2)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Netherlands (2) · Singapore (2) · South Korea (2) · Spain (2) · Switzerland (2) · Taiwan (2)